Home use expansion NovaSight is expanding CureSight for home use amblyopia treatment, positioning opportunities to sell to families and telemedicine providers seeking at-home, compliant alternatives to eye patching.

FDA clearance leverage With FDA 510 clearance for CureSight and recent US market entry, there is a strong case to approach pediatric clinics, schools, and payers about adopting validated digital therapy solutions for amblyopia.

AI driven outcomes The real-time AI and big data driven treatment adjustments and progress monitoring create cross-sell potential with sleep/vision wellness programs, remote patient monitoring platforms, and telehealth partners.

Ambulatory screening EyeSwiftPRO automated eye-tracking screening offers a scalable tool for early detection; potential sales angles include pediatric practices, vision screenings in schools, and community health programs.

MedTech recognition Recent MedTech Breakthrough award and strong funding history enhance credibility when approaching distributors, insurers, and hospital networks looking for innovative pediatric ophthalmology solutions.